Collectively, our findings suggest that the underlying cause of osteoporosis and skeletal dysplasia in patients with pathogenic variants in SGMS2 is not a reduced cellular capacity to synthesize sphingomyelin but rather a perturbation in sphingomyelin metabolism at the plasma membrane. This evidence concerns the gene SGMS2 and osteoporosis.